Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying those that can fulfill their potential is challenging [1] Group 1: Company Overview - Epam (EPAM) is currently highlighted as a recommended growth stock based on the Zacks Growth Style Score, which evaluates a company's growth prospects beyond traditional metrics [2] - The company has a favorable Growth Score and a top Zacks Rank, indicating strong potential for performance [2] Group 2: Earnings Growth - Historical EPS growth for Epam stands at 6.5%, but projected EPS growth is significantly higher at 28.2% for the current year, surpassing the industry average of 24% [4] Group 3: Asset Utilization - Epam's asset utilization ratio is 1.11, meaning it generates $1.11 in sales for every dollar of assets, which is more efficient than the industry average of 0.93 [5] Group 4: Sales Growth - The company's sales are expected to grow by 14.9% this year, compared to the industry average of 5.3%, indicating strong sales growth potential [6] Group 5: Earnings Estimate Revisions - The current-year earnings estimates for Epam have been revised upward, with the Zacks Consensus Estimate increasing by 3.6% over the past month, suggesting positive momentum [8] Group 6: Investment Positioning - Epam has achieved a Growth Score of B and a Zacks Rank of 2 due to positive earnings estimate revisions, positioning it well for potential outperformance in the growth stock category [10]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves significant challenges and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score simplifies the process of identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Progyny (PGNY) is currently highlighted as a recommended growth stock, featuring a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly desirable as it indicates strong future prospects [4] - Progyny has a historical EPS growth rate of 15.2%, but projected EPS growth for this year is expected to be 500%, significantly surpassing the industry average of 14.6% [5] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for assessing efficiency in growth investing [6] - Progyny's S/TA ratio stands at 1.75, indicating that the company generates $1.75 in sales for every dollar in assets, compared to the industry average of 0.76 [6] Group 4: Sales Growth - Sales growth is another key indicator, with Progyny expected to achieve a sales growth rate of 9.2% this year, while the industry average is projected at 0% [7] Group 5: Earnings Estimate Revisions - Trends in earnings estimate revisions are correlated with stock price movements, making them a valuable indicator for investors [8] - Progyny's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 8% over the past month [9] Group 6: Overall Positioning - Progyny has achieved a Zacks Rank of 2 due to positive earnings estimate revisions and has earned a Growth Score of A based on several favorable metrics [11] - This combination positions Progyny well for potential outperformance, making it an attractive option for growth investors [11]

Core Viewpoint - The article highlights Agilysys (AGYS) as a promising growth stock, emphasizing its strong earnings and cash flow growth, as well as positive earnings estimate revisions, making it a solid choice for growth investors [2][10]. Earnings Growth - Agilysys has a historical EPS growth rate of 6.7%, but the projected EPS growth for this year is significantly higher at 58.3%, surpassing the industry average of 53.2% [4]. Cash Flow Growth - The year-over-year cash flow growth for Agilysys stands at 49.9%, which is notably higher than the industry average of 13.8% [5]. - Over the past 3-5 years, the annualized cash flow growth rate for Agilysys has been 33.9%, compared to the industry average of 11.6% [6]. Earnings Estimate Revisions - The current-year earnings estimates for Agilysys have increased, with the Zacks Consensus Estimate rising by 8.5% over the past month [8]. - This upward trend in earnings estimate revisions contributes to Agilysys earning a Zacks Rank of 2 (Buy) and a Growth Score of B [10].

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 50.8% for the current year, significantly outperforming the industry average of 12.2% [5][4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, which is substantially higher than the industry average of 2.6%. Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.2% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 6% over the past month, indicating strong near-term stock price movement potential [8][10]. Overall Positioning - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, positioning it well for potential outperformance in the growth stock category [10].

Group 1 - Regencell Bioscience Holdings has experienced a significant increase in share price, surging 9,800% year to date as of November 19, 2023 [1] - The company focuses on the research, development, and commercialization of Traditional Chinese Medicine for neurocognitive disorders, specifically ADHD and Autism Spectrum Disorder [2] - Despite its exciting mission, Regencell has reported $0 in revenue for the years 2021 through 2025, indicating ongoing financial losses [2][4] Group 2 - The company executed a 38-for-1 stock split in June 2023 after a dramatic price increase of approximately 60,000%, which may have created a misleading sense of value among investors [4] - Regencell's market capitalization recently topped $6 billion, raising concerns about its valuation given the lack of commercial products [4][7] - Analysts suggest that there are better investment opportunities available, as Regencell appears to be a risky bet with no revenue generation for several consecutive years [6][7]

Group 1 - The article highlights the importance of focusing on companies with consistent revenue gains in a challenging macroeconomic environment, particularly those with strong analyst support and solid fundamentals [3][4] - Pinterest Inc. has seen a resurgence in its user base, reaching 600 million monthly active users, marking the ninth consecutive quarter of record highs, driven largely by engagement from Gen Z users [4][5] - In the third quarter, Pinterest's revenue increased by 17% year-over-year, surpassing $1 billion, with management forecasting revenue to exceed $1.3 billion in the next quarter [5] Group 2 - Despite its growth, Pinterest faces challenges such as adapting to AI advancements and a significant decline in ad pricing, which fell nearly 25% year-over-year, although impressions increased [6][7] - The article notes that companies like Pinterest, Spotify, and Snowflake have reported substantial revenue gains and high customer engagement rates, even as consumers face inflation and economic concerns [6]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Ensign Group (ENSG) is highlighted as a recommended growth stock due to its favorable Growth Score and top Zacks Rank [2] - The company operates in the nursing and rehabilitative care services sector, which is currently positioned for growth [3] Group 2: Earnings Growth - Ensign Group has a historical EPS growth rate of 14.5%, with projected EPS growth of 18.2% for the current year, significantly outperforming the industry average of -3.2% [5] Group 3: Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 15.8%, surpassing the industry average of 9.4% [6] - Over the past 3-5 years, Ensign Group's annualized cash flow growth rate has been 17.4%, compared to the industry average of 5.8% [7] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Ensign Group, with the Zacks Consensus Estimate for the current year increasing by 1.4% over the past month [8] Group 5: Investment Positioning - Ensign Group holds a Growth Score of B and a Zacks Rank of 2, indicating strong potential for outperformance, making it an attractive option for growth investors [10]

Core Insights - A unique set of circumstances has created significant value for investors [1] - Among all researched companies, this growth stock presents the best risk-reward ratio currently [1] Company Analysis - The stock prices referenced were from the afternoon of November 17, 2025 [1] - The video discussing this analysis was published on November 19, 2025 [1]

Core Insights - Intuitive Surgical's business model is primarily based on the sale of da Vinci surgical robots, but the real growth driver lies in its parts and services revenue stream [1][2][8] - The company has seen a significant increase in the number of da Vinci systems in use, with a 13% year-over-year growth in Q3 2025, leading to a nearly 33% increase in revenue from the "systems" segment [5][9] - The revenue breakdown shows that while "systems" sales account for about 25% of total revenue, the majority comes from instruments and accessories, which make up around 60% of overall sales [6][7] Revenue Breakdown - The income statement of Intuitive Surgical is divided into three main segments: systems (da Vinci robots), services, and instruments and accessories [4][7] - Services contribute approximately 15% to the top line, primarily from servicing da Vinci robots, while instruments and accessories are the largest revenue source [7] - The growth in surgeries performed using da Vinci systems (20% increase) outpaces the growth in the number of new systems sold, indicating a strong potential for parts and services revenue [8][12] Market Position - Intuitive Surgical is considered a growth stock, with a current market capitalization of $200 billion and a price-to-earnings (P/E) ratio of 72x, significantly higher than the S&P 500 average [9][11] - The company’s P/E ratio aligns with its five-year average, suggesting that while it is expensive relative to the market, it is consistent with its historical valuation [11] - Over the next decade, the revenue from parts and services is expected to increase, potentially making up as much as 80% of total revenue, indicating a shift towards more stable, annuity-like income [9][12]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - TTM Technologies (TTMI) is currently highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive as it indicates strong future prospects [4] - TTM has a historical EPS growth rate of 14.5%, but projected EPS growth for this year is expected to be 42.5%, significantly surpassing the industry average of 25% [5] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for assessing a growth stock's efficiency in generating sales [6] - TTM's S/TA ratio stands at 0.78, indicating that the company generates $0.78 in sales for every dollar in assets, which is higher than the industry average of 0.72 [6] Group 4: Sales Growth - Sales growth is another vital aspect, with TTM expected to achieve an 18.1% sales growth this year, contrasting sharply with the industry average of 0% [7] Group 5: Earnings Estimate Revisions - Trends in earnings estimate revisions are crucial, as positive revisions correlate strongly with stock price movements [8] - TTM's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 5.6% over the past month [8] Group 6: Overall Positioning - TTM has earned a Growth Score of A and holds a Zacks Rank 2 due to positive earnings estimate revisions, positioning it well for potential outperformance in the growth stock category [10]